Janssen Biotech Inc. has succeeded in pushing back the earliest launch date for Pfizer Inc.'s biosimilar to Remicade (infliximab), though it may still come sooner than Janssen wishes.
Celltrion Inc. and US marketing partner Pfizer previously agreed not to launch Inflectra (infliximab-dyyb) in the US before June...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?